Explore the FDA-approved Tyruko, a biosimilar to Tysabri, which has shown comparable safety and efficacy in phase 3 clinical trials for treating relapsing forms of MS.

Discover the exciting research on the DR4 allele, a genetic variant that not only reduces the risk of Alzheimer’s but also offers protection against Parkinson’s disease. Explore the potential for targeted therapies and preventive measures.

New research suggests that a significant portion of patients with post-viral syndrome may have been exposed to SARS-CoV-2, raising questions about their exclusion from long COVID clinics and research. Learn more about the implications for patient care and research inclusion criteria.

Explore the clinical insights into lumateperone, a second-generation antipsychotic showing promise in treating schizophrenia, and learn how understanding effect sizes can guide your treatment decisions.

Discover the latest advancements in ADHD therapies that promise greater efficacy and fewer side effects—options that can revolutionize personalized treatment plans.

Explore how a paradigm shift from monoamine to GABAergic systems could offer new, more effective treatments for major depressive disorder; the latest review discusses the unmet needs and the promising potential of NAS GABAA receptor PAMs.